Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

NCT00929201 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Sitagliptin phosphate/metformin hydrochloride FDC
DRUG: Sitagliptin phosphate
DRUG: Metformin hydrochloride

Sponsor

Merck Sharp & Dohme LLC